Hmm.. odd.. They're only selling the (older) Crusoe line. Not so much
'odd' that Transmeta wanted to do this, more 'odd' in that I can't
understand how this Culturecom company plans to make any money off
buying this processor. The company isn't even getting a license to
the entire chip, they'll apparently still need to pay royalties for it
as well as for the Efficeon.
I could MAYBE understand this if Crusoe or Efficeon were low-cost
chips like VIA's C3, but they aren't really that cheap to produce. At
113mm^2 on a 130nm process the Efficeon is actually larger than an
AthlonXP/Sempron with 512KB of cache (101mm^2) and not far off the
131mm^2 of a 130nm Pentium4 (ie Northwood). Crusoe's 55m^2 die makes
it a bit more economical, though the trade-off here is abysmal
performance (about on-par with a 1998 era 400MHz Celeron).
I just don't get it. Transmeta's been losing bucketloads of money on
a product that costs too much for the performance it delivers, but now
another company thinks they can do better by taking it to a different
fab and paying licensing fees? I guess they can eliminate the R&D
costs, but even without those costs Transmeta is REALLY struggling to
break-even (last quarter showed $6.86M in revenue and $28.08M in
expenses of which only $12.22M were listed as R&D costs).